Top Abstract Purchase Related
Home
>
Node
>
Subnode

Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer

Rubens, R.D.; Hayward, J.L.

Cancer 46(12 Suppl): 2922-2924

1980

ISSN/ISBN: 0008-543X
PMID: 7448737
DOI: 10.1002/1097-0142(19801215)46:12+<2922::aid-cncr2820461435>3.0.co;2-d
Document Number: 451007
In a consecutive series of 191 patients with advanced breast cancer, the response rate to endocrine treatment was 46/136 (34%) in estrogen receptor positive (ER+) patients, compared with 5/55 (9%) in estrogen receptor negative (ER-) patients (P < 0.01). In a retrospective analysis of 47 patients, the response rate to cytotoxic chemotherapy was 20/33 (62%) for ER+ tumors and 8/14 (57%) for ER-. It is concluded that ER+ tumors have a significantly higher chance of responding to endocrine therapy than do ER- tumors, but that receptor status is not a determinant of response to cytotoxic chemotherapy.

Document emailed within 0-6 h
Secure & encrypted payments

Cocconi, G.; De Lisi, V.; Mori, P.; Bozzetti, C. 1982: Estrogen receptors and response to chemotherapy in advanced breast cancer Tumori 68(1): 67-71
Lippman, M.E.; Allegra, J.C. 1980: Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval Cancer 46(12 Suppl): 2829-2834
Nardelli, G.B.; Lamaina, V.; Siliotti, F. 1986: Estrogen and progesterone receptors status in the prediction of response of breast cancer to endocrine therapy (preliminary report) European Journal of Gynaecological Oncology 7(3): 151-158
Kiang, D.T.; Frenning, D.H.; Gay, J.; Goldman, A.I.; Kennedy, B.J. 1980: Estrogen receptor status and response to chemotherapy in advanced breast cancer Cancer 46(12 Suppl): 2814-2817
Tominaga, T. 1983: Histochemical and biochemical assays of estrogen receptors in breast cancer and significance of endocrine therapy Gan no Rinsho. Japan Journal of Cancer Clinics 29(6): 628-631
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
DeWys, W.D.; Allegra, J.C.; Simon, R.; Lippman, M.B. 1980: A proposed model for the prediction of response to endocrine therapy in breast cancer from the estrogen receptor status of one site and the number of metastatic sites Cancer Research 40(7): 2423-2427
Ciatto, S.; Pacini, P.; Confortini, M.; Massimo, V. 1994: Reliability of immunocytochemical assay of estrogen receptors on breast cancer aspirates as a predictor of clinical response to hormone therapy Acta Cytologica 38(4): 666-667
Miglietta, L.; Vanella, P.; Canobbio, L.; Parodi, M.A.; Guglielmini, P.; Boccardo, F. 2009: Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index Anticancer Research 29(5): 1621-1625
Paone, J.F.; Abeloff, M.D.; Ettinger, D.S.; Arnold, E.A.; Baker, R.R. 1981: The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast Surgery Gynecology and Obstetrics 152(1): 70-74
Jensen, E.V.; Block, G.E.; Smith, S.; Kyser, K.; DeSombre, E.R. 1971: Estrogen receptors and breast cancer response to adrenalectomy National Cancer Institute Monograph 34: 55-70
Bao, G.; Yang, D.-q.; Zhou, B.; Liu, P.; Wang, S.; Cheng, L. 2007: Effect of neoadjuvant chemotherapy on estrogen and progesterone receptors and P53 and CerbB-2 in breast cancer Zhonghua Yi Xue Za Zhi 87(40): 2843-2845
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Nichols, W.C.; Kvols, L.K.; Ingle, J.N.; Edmonson, J.H.; Ahmann, D.L.; Rubin, J.; O'Connell, M.J. 1978: Phase Ii study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy Cancer Treatment Reports 62(5): 837-839
Kiang, D.T. 1984: Correlation between estrogen-receptor proteins and response to chemotherapy in patients with breast cancer Cancer Treatment Reports 68(4): 577-579
Nomura, Y.; Abe, Y.; Yamagata, J.; Takenaka, K. 1976: Possible retention of the estrogen-binding capacity after endocrine ablation therapy in the rat and human breast cancer Gan 67(1): 101-104
Howell, A.; Harland, R.N.; Barnes, D.M.; Baildam, A.D.; Wilkinson, M.J.; Hayward, E.; Swindell, R.; Sellwood, R.A. 1987: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment Cancer Research 47(1): 300-304
Di Lorenzo, D.; Zaniboni, A.; Simoncini, E.; Marpicati, P.; Montini, E.; Alghisi, A.; Gorni, F.; Marini, G. 1986: Estrogen and progesterone receptors in neoplastic cells of metastatic pleural effusion of breast carcinoma before and after tamoxifen therapy. Correlation with the clinical response Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 5(4): 232-236
Nomura, Y.; Yamagata, J.; Kondo, H.; Takenaka, K. 1978: Endocrine adjuvant therapy with the antiestrogen, mepitiostane, inoperable breast cancer patients on the basis of estrogen receptor assay Gan 69(2): 281-282
Iglódi, F. 1989: Endocrine therapy monitored by hormone cytological examination in advanced female breast cancer Therapia Hungarica 37(4): 205-208